A planned later-stage trial for a Covid-19 vaccine from Inovio Pharmaceuticals Inc. is on hold, after U.S. health regulators raised questions, the company said. The delay means the Phase 2/3 trial for Inovio’s experimental vaccine won’t begin until October at the earliest. Inovio shares fell as much as 33% on Monday after the trial hold was...

Source: Wall Street Journal September 28, 2020 14:58 UTC